Retatrutide 50mg
Ships from USA
1–3 day delivery
Free Shipping
On orders $150+
Peptide Handling & Storage Guide
Storage temperature, shelf life & reconstitution (PDF)
99%+ Purity
COA included
Same-Day Shipping
Orders before 2PM EST
Secure Checkout
SSL encrypted
Shipment Protection
Lost or damaged — reshipped free
Compound Information
- Type
- GLP-1 / GIP / glucagon triple receptor agonist
- Molecular Formula
- C221H342N46O68
- Molecular Weight
- 4731.42 g/mol
- CAS Number
- 2381089-83-2
- Purity
- 99%
- Also known as
- LY3437943
Reference chemistry (free base) from public chemical databases and peer-reviewed literature. For laboratory research identification only.
Research Use Only. Not for human consumption. For laboratory and scientific research purposes only.
About Retatrutide
Retatrutide, developed by Eli Lilly under the code LY3437943, is a synthetic, fatty-acid-acylated peptide engineered to activate three metabolic hormone receptors at once — the GIP, GLP-1, and glucagon (GCG) receptors — a design described as a "triple-hormone-receptor agonist." The fatty-diacid side chain promotes albumin binding and a long circulating half-life. It sits alongside the single- and dual-agonist incretin peptides semaglutide (GLP-1) and tirzepatide (GIP/GLP-1), from which it differs by adding glucagon-receptor activity.
Retatrutide is an investigational compound: it is not approved by the FDA or any other regulatory authority. Its distinguishing feature as a research reagent is receptor coverage — where semaglutide engages the GLP-1 receptor alone and tirzepatide engages GIP and GLP-1, retatrutide adds glucagon-receptor activity, which is why the three are often compared as a series in receptor-pharmacology work. This product is supplied strictly for in vitro and laboratory research use and is not for human or veterinary use.
Frequently Asked Questions
What is Retatrutide?
Retatrutide (LY3437943) is an investigational synthetic peptide that activates three receptors — GIP, GLP-1, and glucagon — as a single molecule. It is not an approved drug and is supplied here for laboratory research use only, not for human or veterinary use.
Is Retatrutide an approved medicine?
No. Retatrutide is investigational and has not been approved by the FDA or any other regulatory authority. The material listed here is a research chemical for in vitro and laboratory use only and is not for human use.
Is Retatrutide a peptide?
Yes. Retatrutide is a synthetic, fatty-acid-acylated peptide (CAS 2381089-83-2; molecular formula C221H342N46O68) rather than a small molecule, engineered to act on the GIP, GLP-1, and glucagon receptors. The fatty-diacid side chain promotes albumin binding. It is supplied for laboratory research use only.
How is Retatrutide different from semaglutide and tirzepatide?
They differ in how many receptors they engage. Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist; retatrutide adds a third target, the glucagon receptor, making it a GLP-1/GIP/glucagon triple agonist. All three are provided here for laboratory research use only.
Related Research Peptides
Research & References
Independent databases and peer-reviewed literature for Retatrutide. Provided for research reference only.
External resources are independent and not affiliated with or endorsed by PHIOGEN. Listed for laboratory research reference only.
